Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss

Gym bros call it "reta." Eli Lilly is calling it the winner. On Wednesday, the pharmaceutical giant announced the results of the first clinical trial pitting Ozempic against its newest, most powerful, and yet-to-be-approved next-generation injectable medication for obesity and diabetes:…

Open True Mainstream to compare left, right, and center coverage

1,600+ newsrooms tracked, in English, around the clock. Real newsrooms only — no NGOs, no press releases. Left/Right tags come from reader feedback. No algorithmic feed.